Plasmalogen Deficiency, Microglial Activation, and Their Role in ME-CFS and Long COVID

#brain_health #therapy

Summary

Here is a summary from: https://www.healthrising.org/blog/2023/07/24/plasmalogen-chronic-fatigue-syndrome-long-covid/

The article from Health Rising discusses a new hypothesis regarding the overlap between Long Covid symptoms and ME-CFS. Here's a summary of the key points:

  1. Researcher Introduction: Dr. Marie-Eve Tremblay, a distinguished Canadian researcher, has joined the research on ME/CFS and long-COVID.

  2. New Model: The model suggests that inflammation and microglial activation, which have been discussed for a long time, are combined with a newer factor – plasmalogen deficiency. This research builds upon previous findings, suggesting a coherent understanding of the disease.

  3. Microglial Activation: Microglia are immune cells in the brain. The hypothesis suggests that inflammation makes these cells hyperactive, causing them to overreact to minor threats, leading to excessive inflammation.

  4. Plasmalogen Deficiency: Plasmalogens are essential components of cell membranes. A deficiency in plasmalogens could damage cell membranes, affecting their function. This deficiency has been observed in several neurodegenerative diseases and might play a significant role in ME/CFS and long COVID.
    See more info here:

  1. Peroxisomes: These are cellular structures where plasmalogens are synthesized. The article suggests that oxidative stress might be damaging plasmalogens in ME/CFS, leading to a vicious cycle affecting cellular health.

  2. Breakthrough Paper: A study from Ian Lipkin's group tied together findings of plasmalogen deficiency, peroxisome issues, reduced carnitine levels, and impaired mitochondrial function.

  3. Immune Exhaustion: There's a suggestion that poor energy production in ME/CFS might be affecting the immune system's ability to respond to threats.

  4. Treatment: The article discusses "plasmalogen replacement therapy" (PRT) as a potential treatment. While not yet tested for ME/CFS or long COVID, it's believed to be a promising approach.

    • Plasmalogen Replacement Therapy (PRT):
      • How It Works: This potential treatment aims to boost plasmalogen levels in the body. Plasmalogens protect neurons and glial cells against multiple kinds of injury and might reduce neuroinflammation.
      • Status: Has not yet been tested in ME/CFS or long COVID. The dosage and other specifics are not provided in the article.
      • Note: Current commercial options for PRT are primarily dietary supplements like ProdomeNeuro and ProdomeGlia. Specific PRT treatments in development may not yet be available to the public.
      • More info:
  5. Plasmalogen Supplements: Several supplements are available that claim to boost plasmalogen levels. One such supplement, ProdomeNeuro, is said to be highly potent. However, these supplements can be expensive.

  6. Conclusion: The article emphasizes the potential significance of plasmalogens in understanding and treating ME/CFS and long COVID. While it's too early to conclude their effectiveness, the involvement of researchers like Dr. Tremblay makes plasmalogen supplementation an intriguing area of study.

The article concludes by offering readers the opportunity to register for Health Rising's free ME/CFS and Fibromyalgia blog for more in-depth information on the latest research and treatments.


Other Known Supplements


Sources

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203127/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804645/